Disposable pen-type injector for diabetes therapy


DCA Design International Ltd 、Sanofi-Aventis Deutschland GmbH







Lyxumia®の概要Lyxumia® pen is a new disposable injector, intended to help people with type 2 diabetes. Each pen contains 300mcg of glucagon-like peptide-1 (GLP-1) solution that can be injected in three dose sizes (10, 15 or 20mcg).The device design prioritizes safety and usability, which are of critical importance to the many users for whom Lyxumia® will be the first experience of self-injection.The product is simple to operate, but contains a clever mechanism that makes doses smooth and easy to deliver. Distinctive tactile features, colors and graphics are applied to enhance product differentiation.
プロデューサーSanofi Aventis Deutschland GmbH, Site Frankfurt Devices, Building H500, Industriepark Hoechst, Frankfurt-am-Main, Germany.
ディレクターUdo Stauder, Michael Noderer, Sanofi Aventis Deutschland GmbH, MED, Building K607, Industriepark Hoechst, Frankfurt-am-Main, Germany.
デザイナーDCA Design International Ltd., 19 Church Street, Warwick, CV43 4AB, UK.
The Lyxumia® pen is designed with the comfort and convenience of users in mind; especially those who are not familiar with self-injection. The pen is exceptionally simple to learn and convenient to use. With a precise dialling action, a clear dose display, a short dial extension and a low injection force; selecting and injecting the required dose is made easy and re-assuring for all users.
With a distinctive and stylish design, the Lyxumia® pen fits in easily with the lifestyle of diabetes patients. The device is convenient, portable and designed to be disposed of when the medicament cartridge is exhausted after a few weeks of use. The pen is intended to support better compliance with prescribed treatment regimens, which in turn should optimize therapeutic benefit for patients.
Carefully designed for efficient, high-volume manufacture using fully automated assembly equipment, the Lyxumia® pen is a state-of the art-device. The pen is the result of a rigorous design and development programme in which the component geometry and materials have been optimized to provide robust and reliable performance, with just thirteen parts.
Bringing the new Lyxumia® medication to the market quickly in a convenient and efficient package, this new pen is intended to make a difference to people living with type 2 diabetes in Japan.
ユーザー・社会に伝えたいことLyxumia® is a simple new medication intended to help patients with type 2 diabetes achieve better glycaemic control and weight loss. It is another step forward in our efforts to create therapies that improve patient outcomes. Designed specifically for this important medication; the exciting new Lyxumia® pen provides a convenient, comfortable and re-assuring tool for self-injection of GLP-1.
どこで購入できるか、どこで見られるかUsers (diabetes patients) can purchase (be prescribed) only from medical institutes (hospitals or pharmacies).、Sanofi KK, Device Marketing, Diabetes Business Unit, Tokyo.[RET]
Lyxumia®をもっと見る・購入 楽天市場でLyxumia®を探す




著作権利者:(C)JIDPO GOOD DESIGN AWARD [ G-Mark Library ]